Skip to main content
Premium Trial:

Request an Annual Quote

Healthcare Firm Taps Instem's Products to Support Drug R&D Efforts


Instem said this week, than an undisclosed healthcare company has licensed its Centrus software suite and SRS platform to support ongoing drug research and development efforts.

The Centrus suite provides users with a single, secure environment to access, harmonize, and use early drug development information from a variety of sources, including data acquisition systems, warehouses, as well as partner and contract research applications. The suite includes Centrus submit, which lets users convert data into the Standard for Exchange of Non-Clinical Data, or SEND, format — a standard developed by the Clinical Data Interchange Standards Consortium for non-clinical data collected from animal toxicology studies.

Instem said its new customer has also licensed SRS, its genomic data integration platform, to help researchers access, integrate, and query SEND data being created from their own preclinical data collection system as well as SEND data received from their external study partners.

The financial details of the agreement are not being disclosed.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.